REDWOOD CITY, Calif.–(BUSINESS WIRE)–Mar 14, 2013–Pathwork Diagnostics, Inc., the innovator of the Pathwork ® Tissue of Origin Test and a pioneer in creating genomics-based diagnostics in oncology, announced today that it has entered into an agreement with Kindstar Global (Kindstar) to provide them with the FDA cleared in vitro diagnostic (IVD) kit version of the Pathwork Tissue of Origin Test. The agreement supports Pathwork’s efforts to improve cancer care worldwide, expands Pathwork’s international network of test and service providers, and is the first IVD kit agreement for Pathwork.
The collaboration will allow Kindstar to offer an important new test for cancer diagnosis in China. Cancers are treated differently based on what type of cancer they are. When the disease is metastatic at the time of diagnosis, determining the type of cancer can be especially difficult.
“The Pathwork Tissue of Origin test is a valuable complement to immunohistochemistry in determining site of origin for lesions that are poorly differentiated or show staining and morphology patterns that are inconsistent with clinical expectations,” said Lee McCracken, President and CEO of Pathwork Diagnostics. “We are pleased to partner with Kindstar and provide the rapidly expanding Chinese market with access to our innovative test.” “We are excited about offering the Tissue of Origin test,” says Shiang Huang, M.D., founder and CEO of Kindstar. “Having access to this test will allow us to expand the current testing services we offer Chinese physicians and position our business as the leading diagnostic company in the fastest growing market in the world.” About Kindstar Diagnostics Co. Kindstar Diagnostics Co., Ltd., with laboratory facilities in Beijing, Shanghai and Wuhan, provides esoteric diagnostic testing services to hospitals and physicians in every province of China. Kindstar is the first and largest esoteric diagnostic testing business in China, providing laboratory testing services to over 3,300 Chinese hospitals, including 930 large leading hospitals (Class III A and B). Kindstar is becoming the partner of choice to physicians in China for advanced diagnostics in many medical specialties including hematology, oncology, infectious diseases and medical genetics.
About the Pathwork Tissue of Origin Test
The company’s Pathwork ® Tissue of Origin Test is the only FDA-cleared, Medicare-covered molecular diagnostic test for tissue of origin. It uses a tumor’s own genomic information to help pathologists and oncologists in the diagnosis of challenging cancer cases such as those that are metastatic or that have a complex clinical history.
The Pathwork Tissue of Origin Test, available through the Pathwork Diagnostics Laboratory, measures gene expression levels of 2,000 genes and uses proprietary algorithms to compare the tumor’s gene expression pattern to that of 15 tumor types, representing 58 morphologies and 90% of all solid tumors. The test provides objective genomic information to help the physician diagnose what type of cancer the patient has. Diagnosis allows oncologists to match therapy to the cancer.
About Pathwork Diagnostics
Pathwork Diagnostics created its proprietary informatics platform to develop high-value, medically important diagnostics aimed at helping guide cancer care. Pathwork has commercialized its first product, the Pathwork Tissue of Origin Test, and is poised to further aid oncologists and pathologists through development of clinical products based on genomic analysis. Pathwork is privately held and based in Redwood City, CA. Key investors include Abingworth, Prospect, Novus and Venrock. For more information, visit www.pathworkdx.com.